Skip to content

Clinical trials

Pancreatic Neoplasms trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pancreatic Neoplasms Country / region: France Clear all

226 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20012
20021
20034
20043
20054
20064
20076
200810
20097
20101
201112
20124
20133
20148
20159
201613
20179
201813
20199
202010
202118
202217
202310
202418
202510
202610

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed102
Recruiting40
Unknown status28
Terminated28
Active, not recruiting20
Not yet recruiting6
No longer available1
Approved for marketing1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Institut Paoli-Calmettes15
Eli Lilly and Company13
GERCOR - Multidisciplinary Oncology Cooperative Group12
Assistance Publique - Hôpitaux de Paris8
European Organisation for Research and Treatment of Cancer - EORTC5
Federation Francophone de Cancerologie Digestive5
Novartis Pharmaceuticals5
Pfizer5
University Hospital, Montpellier5
Amgen4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pancreatic Neoplasms226
Colorectal Neoplasms29
Neoplasms29
Carcinoma, Non-Small-Cell Lung23
Ovarian Neoplasms22
Stomach Neoplasms21
Neoplasm Metastasis20
Breast Neoplasms18
Lung Neoplasms18
Esophageal Neoplasms17

Trials

Showing 1 to 25 of 226. Each trial links to its page on Pharma Observatory.

126 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.